Oppenheimer Starts Humacyte (HUMA) at Outperform

September 23, 2021 4:03 PM EDT
Get Alerts HUMA Hot Sheet
Price: $9.09 +3.77%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 9 | Down: 13 | New: 18
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Oppenheimer analyst Suraj Kalia initiates coverage on Humacyte (NASDAQ: HUMA) with an Outperform rating and a price target of $16.00.

The analyst commented, "We are initiating coverage of Humacyte, a recent SPAC merger, with an Outperform rating/$16 PT. An early-stage play in bioengineered vascular grafts, Humacyte has pioneered a human acellular vessel (HAV) for use in vascular grafting. Early results in various Ph2 and POC studies are showing encouraging results in graft patency, ease of use, AE profile, and durability vs. current standard of care—autologous/ePTFE grafts. Fresenius Medical, a key investor in Humacyte, has signed an OUS distribution agreement for HAV. We view Humacyte in two discrete facets—the immediate commercial opportunity in AV access for dialysis and vascular trauma; and the call option in T1 diabetes, which could be paradigm changing. We advise this name only to high-risk tolerance long-duration investors."

For an analyst ratings summary and ratings history on Humacyte click here. For more ratings news on Humacyte click here.

Shares of Humacyte closed at $13.25 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Definitive Agreement, SPAC